polatuzumab vedotin + rituximab + lenalidomide

Polatuzumab vedotin + rituximab + lenalidomide is an investigational **combination therapy** for the treatment of relapsed or refractory **diffuse large B-cell lymphoma (DLBCL)**, particularly in patients ineligible for stem cell transplantation[1][4][5][6]. This combination includes three agents: - **Polatuzumab vedotin**: an antibody-drug conjugate targeting CD79b on B cells, delivering the cytotoxic agent monomethyl auristatin E, which disrupts microtubule function and induces cell death[2]. - **Rituximab**: a monoclonal antibody against CD20, leading to immune-mediated B-cell depletion. - **Lenalidomide**: a small molecule immunomodulatory agent that has antiproliferative, antiangiogenic, and immune-enhancing properties. Clinical trials (notably the Phase Ib/II GO29834 study) have shown that this triplet regimen can induce responses in heavily pre-treated DLBCL patients, with a tolerable safety profile[1][4][5][6]. The most common high-grade adverse events were neutropenia and infections[1][4]. The combination has not met prespecified activity thresholds compared to historical controls but has demonstrated meaningful clinical benefit for some patients, especially those with limited options[1][5][6].

Brand names

PolivyRituxanRevlimid

Other names

Pola-R-LenPola+R+Len